Industry Verticals »

All Categories

Insights »

About TMR »

High Potency Active Pharmaceutical Ingredients (HPAPI) Market

High Potency Active Pharmaceutical Ingredients (HPAPI) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global High Potency Active Pharmaceutical Ingredients (HPAPI) market for the historical period 2017–2018 and forecast period 2019–2027, growing preference for outsourcing of HPAPI manufacturing and rich pipeline with targeted therapeutic drugs are the factors likely to boost the growth of the market. However, containment of technical expertise in the hands of few major players and lack of universal regulatory policies and standards is poised to escalate the growth of the market.
  • According to the report, the global market was valued at US$ 17.45 Bn in 2018 and is anticipated to expand at a CAGR of over 8.7% from 2019 to 2027
high potency active pharmaceutical ingredients market

To know the scope of our report Get a Sample on High Potency Active Pharmaceutical Ingredient (HPAPI) Market

Growing preference for outsourcing of HPAPI manufacturing and rich pipeline with targeted therapeutic drugs: Key Drivers of the Market

  • Pharmaceutical companies were skeptical in outsourcing manufacture of high potency APIs, and majority of the manufacturing was confined to captive or in-house. Major factor behind this was risk of patent infringement. However, as pharmaceutical companies started to expand geographical boundaries, they started experiencing shortage of HPAPIs. Furthermore, increasing cost of drug development and commercialization added to the financial burden. With developing regulatory and legal framework, outsourcing proved to be the most optimal option for HPAPI manufacturing.
  • Pharmaceutical companies can now focus on core business activities such as drug development and commercialization, while also take advantage of technical expertise at CMOs instead of investing in expensive HPAPI manufacturing setup.
  • Pharmaceutical companies have made significant investments in development of innovative drugs with targeted mode of action. Specific action and little or no side effects are major advantages for preference of such drugs. Various research articles published suggest that over 25% of the drugs in pipeline incorporate high potency active pharmaceutical ingredient (HPAPI). Currently only two antibody-drug conjugated drugs have been approved: Adcertis (Brentuximab vedotin) and Kadcyla (Trastuzumab emtansine). There are two other late stage candidates Inotuzumab ozogamicin (by, Pfizer) and IMMU-107 (by, Immunomedics). Several monoclonal antibody drugs are also expected to hit the High Potency Active Pharmaceutical Ingredients (HPAPI) Market in the near future. Palivizumab, ofatumumab, KW-0761, and pembrolizumab are only a few examples of monoclonal antibody drugs in phase 3.
  • With increasing number of potential phase 3 drug candidates, demand for contract manufacturing of HPAPIs has increased significantly in the recent past, and is one of the major drivers of the global HPAPI market.

Get a glimpse of the in-depth analysis through our Report Brochure

Patent Expiry of Blockbuster Drugs Propel the Global Market Growth

  • Patent expiry and subsequent launch of generic versions is a lucrative opportunity for pharmaceutical companies to expand product portfolio and tap profitable market segments in this technology driven market. Various biosimilar have been approved in Europe, while the U.S. FDA has approved only one biosimilar to date. Increase in research and development activities and constant attempts toward mimicking branded biological drugs would pave the way for introduction of cost-effective treatment alternatives.
  • Various blockbuster drugs are expected to loose patent protection in the near future, providing large opportunities in the biosimilar market. Avastin (bevacizumab), Herceptin (trastuzumab), Synagis (palivizumab), Erbitux (cetuximab), Humira (adalimumab), Remicade (infliximab), and Rituxan (rituximab) are some of the major drugs going off patent in the near future.

Containment of Technical Expertise in the Hands of Few Major Players to Hamper the Market

  • High potency API manufacturing is capital intensive and requires skilled technical know-how; this has been a major barrier for new entrants who wish to tap the lucrative HPAPI market. Currently, few major players exist who have built their own capabilities through mergers, acquisitions, partnerships, and research and development.
  • Hence, the global HPAPI manufacturing market is leaning toward consolidation of expertise in the hands of few global players. Lonza, Novasep, SAFC, Cambrex, Teva API, Dr. Reddy’s Laboratories, and WuXi are key players in the HPAPI market.

Lack of Universal Regulatory Policies and Standards to Restrain the Market

  • The high potency API market is a rapidly growing market with large numbers of players looking to invest in building capabilities for manufacturing of HPAPIs. HPAPIs are highly toxic to human body. Hence, high level of care is taken during manufacturing of these compounds. Despite these complications, there does not exist any specific occupational health, safety, and environmental protection regulations that cover manufacturing of HPAPIs.
  • Private organizations such as Merck, Lonza, and SafeBridge have taken initiative to classify HPAPIs and (occupational exposure limits) OELs. However, CMOs need to maintain manufacturing standards as per client requirements due to lack of a universal guidelines. Introduction of universal guidelines and manufacturing policies would also provide credibility to CMOs, thus helping pharmaceutical companies in outsourcing business.

Expanding operations in future? To get the perfect launch ask for a custom report 

Competitive Landscape

  • This report profiles major players in the global High Potency Active Pharmaceutical Ingredients (HPAPI) industry based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global market are
    • Alkermes plc
    • Cambrex Corporation
    • Dr. Reddy's Laboratories
    • Lonza Group
    • Novasep
    • Novartis AG
    • Pfizer
    • Sigma-Aldrich Co. LLC.
    • WuXi AppTec
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche
    • Teva Pharmaceutical Industries
    • Eli Lilly and Company
    • Abbvie.

Key Developments

Key players in the global High Potency Active Pharmaceutical Ingredients (HPAPI) market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the market. A few expansion strategies adopted by players operating in the global market are:

  • In April 2019, U.S. based Cambrex Corporation expanded its new facility high-potency API production in U.S.
  • In 2018, FDA approved 59 drugs, of that 42 were small molecules and 17 were biologics which accounts to about 28.8% of total approvals which has risen from 26.1% from the year 2017. Few biologic drugs approved in 2018 are Trogarzo, Ilumya, Crysvita, Aimovig, Poteligeo, Emgality, Libtayo and Takyzyro.

The report on the global High Potency Active Pharmaceutical Ingredients (HPAPI) market discussed individual strategies, followed by company profiles of manufacturers of High Potency Active Pharmaceutical Ingredients. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the market

Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market – Segmentation

API Type

Synthetic

Biological

Manufacture Type

Captive

Contract

Drug Type

Branded

Generic

Therapeutic Application

Oncology Drugs

Anti-diabetic Drugs

Cardiovascular Drugs

Academic & Research Centers

Pharmaceutical Companies

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of high potency active pharmaceutical ingredients (HPAPI)?

The global market to reach US$ 36.83 Bn by 2027

What is the anticipated CAGR of the HPAPI market in the forecast period?

The market is anticipated to expand at a CAGR of over 8.7% from 2019 to 2027

What are the key driving factors for the growth of the high potency API market?

High potency API market is driven by growing preference for outsourcing of HPAPI manufacturing and patent expiry of blockbuster drugs

Which region is expected to project the highest market share in the global market?

North America accounted for a major share of the global market and the trend is anticipated to continue during the forecast period

Who are the key players in the market?

Key players in the global market include Alkermes plc, Cambrex Corporation, Dr. Reddy's Laboratories, Lonza Group, Novasep

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Type/Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, 2017–2027

    5. Key Insights

        5.1. Value Chain Analysis

        5.2. Event Impact analysis

        5.3. Epidemiology of Cancer by Country/Sub-region

    6. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by API Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

            6.3.1. Synthetic

            6.3.2. Biological

        6.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Product Type

    7. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Manufacture Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

            7.3.1. Captive

            7.3.2. Contract

        7.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Manufacture Type

    8. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Drug Type

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

            8.3.1. Branded

            8.3.2. Generic

        8.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Drug Type

    9. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Therapeutic Application

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

            9.3.1. Oncology Drugs

            9.3.2. Anti-diabetic Drugs

            9.3.3. Cardiovascular Drugs

            9.3.4. CNS Drugs

            9.3.5. Musculoskeletal Drugs

            9.3.6. Other Drugs 

        9.4. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Therapeutic Application

    10. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecasts, by Region

        10.1. Key Findings

        10.2. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Region

            10.2.1. North America 

            10.2.2. Europe 

            10.2.3. Asia Pacific 

            10.2.4. Latin America 

            10.2.5. Middle East & Africa 

        10.3. Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness by Country/Region

    11. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

            11.2.1. Synthetic

            11.2.2. Biological

        11.3. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

            11.3.1. Captive

            11.3.2. Contract

        11.4. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

            11.4.1. Branded

            11.4.2. Generic

        11.5. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

            11.5.1. Oncology Drugs

            11.5.2. Anti-diabetic Drugs

            11.5.3. Cardiovascular Drugs

            11.5.4. CNS Drugs

            11.5.5. Musculoskeletal Drugs

            11.5.6. Other Drugs

        11.6. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

            11.6.1. U.S.

            11.6.2. Canada

        11.7. North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

            11.7.1. By API Type

            11.7.2. By Manufacture Type

            11.7.3. By Drug Type

            11.7.4. By Therapeutic Application

            11.7.5. By Country

    12. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

            12.2.1. Synthetic

            12.2.2. Biological

        12.3. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

            12.3.1. Captive

            12.3.2. Contract

        12.4. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

            12.4.1. Branded

            12.4.2. Generic

        12.5. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

            12.5.1. Oncology Drugs

            12.5.2. Anti-diabetic Drugs

            12.5.3. Cardiovascular Drugs

            12.5.4. CNS Drugs

            12.5.5. Musculoskeletal Drugs

            12.5.6. Other Drugs

        12.6. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

            12.7.1. By API Type

            12.7.2. By Manufacture Type

            12.7.3. By Drug Type

            12.7.4. By Therapeutic Application

            12.7.5. By Country/Sub-region

    13. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

            13.2.1. Synthetic

            13.2.2. Biological

        13.3. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

            13.3.1. Captive

            13.3.2. Contract

        13.4. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

            13.4.1. Branded

            13.4.2. Generic

        13.5. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

            13.5.1. Oncology Drugs

            13.5.2. Anti-diabetic Drugs

            13.5.3. Cardiovascular Drugs

            13.5.4. CNS Drugs

            13.5.5. Musculoskeletal Drugs

            13.5.6. Other Drugs

        13.6. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

            13.7.1. By API Type

            13.7.2. By Manufacture Type

            13.7.3. By Drug Type

            13.7.4. By Therapeutic Application

            13.7.5. By Country/Sub-region

    14. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

            14.2.1. Synthetic

            14.2.2. Biological

        14.3. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

            14.3.1. Captive

            14.3.2. Contract

        14.4. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

            14.4.1. Branded

            14.4.2. Generic

        14.5. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

            14.5.1. Oncology Drugs

            14.5.2. Anti-diabetic Drugs

            14.5.3. Cardiovascular Drugs

            14.5.4. CNS Drugs

            14.5.5. Musculoskeletal Drugs

            14.5.6. Other Drugs

        14.6. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

            14.7.1. By API Type

            14.7.2. By Manufacture Type

            14.7.3. By Drug Type

            14.7.4. By Therapeutic Application

            14.7.5. By Country/Sub-region

    15. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by API Type, 2017–2027

            15.2.1. Synthetic

            15.2.2. Biological

        15.3. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Manufacture Type, 2017–2027

            15.3.1. Captive

            15.3.2. Contract

        15.4. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Drug Type, 2017–2027

            15.4.1. Branded

            15.4.2. Generic

        15.5. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Therapeutic Application, 2017–2027

            15.5.1. Oncology Drugs

            15.5.2. Anti-diabetic Drugs

            15.5.3. Cardiovascular Drugs

            15.5.4. CNS Drugs

            15.5.5. Musculoskeletal Drugs

            15.5.6. Other Drugs

        15.6. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Forecast by Country, 2017–2027

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis 

            15.7.1. By API Type

            15.7.2. By Manufacture Type

            15.7.3. By Drug Type

            15.7.4. By Therapeutic Application

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player – Competition Matrix (By Tier and Size of companies)

        16.2. Market Share Analysis/Ranking By Company (2018)

        16.3. Company Profiles

            16.3.1. Alkermes plc,

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Growth Strategies

                16.3.1.3. SWOT Analysis. 

            16.3.2. Cambrex Corporation

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Growth Strategies

                16.3.2.3. SWOT Analysis. 

            16.3.3. Dr. Reddy's Laboratories

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Growth Strategies

                16.3.3.3. SWOT Analysis. 

            16.3.4. Lonza Group

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Growth Strategies

                16.3.4.3. SWOT Analysis. 

            16.3.5. Novasep

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Growth Strategies

                16.3.5.3. SWOT Analysis. 

            16.3.6. Novartis AG

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Growth Strategies

                16.3.6.3. SWOT Analysis. 

            16.3.7. Pfizer

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Growth Strategies

                16.3.7.3. SWOT Analysis. 

            16.3.8. Sigma-Aldrich Co. LLC.

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Growth Strategies

                16.3.8.3. SWOT Analysis. 

            16.3.9. WuXi AppTec

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Growth Strategies

                16.3.9.3. SWOT Analysis. 

    List of Table

    Table 01: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

    Table 02: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

    Table 03: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

    Table 04: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

    Table 05: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 06: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 07: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

    Table 08: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

    Table 09: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

    Table 10: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

    Table 11: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2027

    Table 12: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 13: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

    Table 14: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

    Table 15: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

    Table 16: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

    Table 17: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 18: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 19: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

    Table 20: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

    Table 21: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

    Table 22: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

    Table 23: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 24: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 25: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

    Table 26: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

    Table 27: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

    Table 28: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

    Table 29: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 30: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 31: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by API Type, 2017–2027

    Table 32: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Manufacture Type, 2017–2027

    Table 33: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Drug Type, 2017–2027

    Table 34: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Therapeutic Application, 2017–2027

    Table 35: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 36: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    List of Figure

    Figure 01: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

    Figure 02: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast, 2017–2027

    Figure 03: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

    Figure 04: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Synthetic, 2017–2027 

    Figure 05: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Biological, 2017–2027 

    Figure 06: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

    Figure 07: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

    Figure 08: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Captive, 2017–2027 

    Figure 09: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), By Contract, 2017–2027 

    Figure 10: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

    Figure 11: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

    Figure 12: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oncology Drugs, 2017–2027 

    Figure 13: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-diabetic Drugs, 2017–2027 

    Figure 14: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cardiovascular Drug, 2017–2027 

    Figure 15: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CNS Drugs, 2017–2027 

    Figure 16: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Musculoskeletal Drugs, 2017–2027 

    Figure 17: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027 

    Figure 18: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

    Figure 19: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

    Figure 20: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Branded, 2017–2027

    Figure 21: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Generic, 2017–2027

    Figure 22: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

    Figure 23: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market, by Region, 2018 and 2027

    Figure 24: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Region, 2019–2027

    Figure 25: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 26: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

    Figure 27: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

    Figure 28: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

    Figure 29: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

    Figure 30: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

    Figure 31: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

    Figure 32: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

    Figure 33: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country, 2018 and 2027

    Figure 34: North America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country, 2019–2027

    Figure 35: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 36: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

    Figure 37: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

    Figure 38: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

    Figure 39: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

    Figure 40: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

    Figure 41: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

    Figure 42: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

    Figure 43: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

    Figure 44: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 45: Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 46: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 47: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

    Figure 48: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

    Figure 49: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

    Figure 50: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

    Figure 51: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

    Figure 52: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

    Figure 53: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

    Figure 54: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

    Figure 55: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 56: Asia Pacific High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 57: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 58: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

    Figure 59: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

    Figure 60: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

    Figure 61: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

    Figure 62: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

    Figure 63: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

    Figure 64: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

    Figure 65: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

    Figure 66: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 67: Latin America High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 68: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 69: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by API Type, 2018 and 2027

    Figure 70: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by API Type, 2019–2027

    Figure 71: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Manufacture Type, 2018 and 2027

    Figure 72: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Manufacture Type, 2019–2027

    Figure 73: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Therapeutic Application, 2018 and 2027

    Figure 74: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Therapeutic Application, 2019–2027

    Figure 75: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Drug Type, 2018 and 2027

    Figure 76: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Drug Type, 2019–2027

    Figure 77: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 78: Middle East & Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 79: Global High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share, by Company, 2018 

Copyright © Transparency Market Research, Inc. All Rights reserved

High Potency Active Pharmaceutical Ingredients (HPAPI) Market

Schedule a Call